FDA Approves Keytruda With Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

The FDA has approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum-based chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).

Efficacy was investigated in KEYNOTE-483 (ClinicalTrials.gov. Identifier: NCT02784171), a randomized, open-label trial in patients with unresectable advanced or metastatic MPM and no prior systemic therapy for advanced/metastatic disease. Patients were randomized (1:1) to receive either